TRCT
ABEO icon

Tower Research Capital (TRC)’s Abeona Therapeutics ABEO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.7K Buy
7,516
+3,854
+105% +$19.3K ﹤0.01% 3090
2025
Q4 		$19.3K Sell
3,662
-4,905
-57% -$24.7K ﹤0.01% 3120
2025
Q3 		$45.2K Buy
8,567
+3,509
+69% +$22.3K ﹤0.01% 2606
2025
Q2 		$28.7K Buy
+5,058
New +$28.8K ﹤0.01% 3440
2025
Q1 		– Sell
-5,951
Closed -$33.1K – 5126
2024
Q4 		$33.1K Sell
5,951
-38
-0.6% -$234 ﹤0.01% 2832
2024
Q3 		$37.9K Sell
5,989
-31,988
-84% -$167K ﹤0.01% 2879
2024
Q2 		$161K Buy
37,977
+21,837
+135% +$111K ﹤0.01% 2234
2024
Q1 		$117K Buy
16,140
+14,126
+701% +$89.5K ﹤0.01% 1744
2023
Q4 		$10.1K Sell
2,014
-8,307
-80% -$36.5K ﹤0.01% 4293
2023
Q3 		$43.5K Buy
+10,321
New +$39.1K ﹤0.01% 2667
2023
Q2 		– Sell
-640
Closed -$2K – 6014
2023
Q1 		$2K Sell
640
-16,044
-96% -$41.9K ﹤0.01% 5304
2022
Q4 		$52K Buy
16,684
+16,377
+5,335% +$61.3K ﹤0.01% 2310
2022
Q3 		$1K Sell
307
-1,423
-82% -$5.87K ﹤0.01% 5726
2022
Q2 		$9K Buy
1,730
+1,577
+1,031% +$7.98K ﹤0.01% 4530
2022
Q1 		$1K Sell
153
-607
-80% -$4.17K ﹤0.01% 5737
2021
Q4 		$6K Sell
760
-1,491
-66% -$27.4K ﹤0.01% 5005
2021
Q3 		$63K Buy
2,251
+2,115
+1,555% +$67.7K ﹤0.01% 2768
2021
Q2 		$5K Sell
136
-222
-62% -$9.06K ﹤0.01% 4678
2021
Q1 		$17K Sell
358
-387
-52% -$21.3K ﹤0.01% 3988
2020
Q4 		$29K Sell
745
-2,031
-73% -$69.2K ﹤0.01% 3586
2020
Q3 		$70K Buy
2,776
+2,284
+464% +$144K ﹤0.01% 3385
2020
Q2 		$35K Buy
492
+471
+2,243% +$32.6K ﹤0.01% 3326
2020
Q1 		$1K Buy
+21
New +$1.4K ﹤0.01% 2714
2019
Q4 		– Sell
-18
Closed -$1K – 3435
2019
Q3 		$1K Sell
18
-331
-95% -$24.8K ﹤0.01% 3808
2019
Q2 		$42K Buy
349
+284
+437% +$47.6K ﹤0.01% 1691
2019
Q1 		$12K Hold
65
– – ﹤0.01% 2557
2018
Q4 		$12K Sell
65
-232
-78% -$50.6K ﹤0.01% 2299
2018
Q3 		$95K Buy
+297
New +$105K 0.01% 1377
2018
Q2 		– Sell
-207
Closed -$74K – 3585
2018
Q1 		$74K Buy
+207
New +$76.9K 0.01% 1449
2017
Q4 		– Sell
-20
Closed -$9K – 3445
2017
Q3 		$9K Buy
20
+8
+67% +$2.15K ﹤0.01% 3102
2017
Q2 		$2K Sell
12
-8
-40% -$1.09K ﹤0.01% 2306
2017
Q1 		$2K Sell
20
-85
-81% -$11K ﹤0.01% 2577
2016
Q4 		$13K Buy
+105
New +$16.4K ﹤0.01% 2456
2016
Q3 		– Sell
-20
Closed -$1K – 3544
2016
Q2 		$1K Sell
20
-102
-84% -$6.97K ﹤0.01% 4115
2016
Q1 		$8K Sell
122
-102
-46% -$6.75K ﹤0.01% 2162
2015
Q4 		$19K Buy
+224
New +$22.5K ﹤0.01% 1330
2015
Q3 		– Sell
-811
Closed -$102K – 3906
2015
Q2 		$102K Buy
811
+794
+4,671% +$119K 0.01% 790
2015
Q1 		$1K Sell
17
-7
-29% -$564 ﹤0.01% 3997
2014
Q4 		$2K Buy
+24
New +$2.15K ﹤0.01% 3297

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s ABEO Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Abeona Therapeutics (ABEO) stake by 105% in Q1 2026, buying an estimated $19.3K and bringing the position to 7,516 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Tower Research Capital (TRC) first reported a position in ABEO in Q4 2014 and has held it in 39 quarters since. The position peaked at $161K in Q2 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Tower Research Capital (TRC) held 7,516 shares of Abeona Therapeutics worth $33.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,854 Abeona Therapeutics shares in Q1 2026, an estimated $19.3K.
  • Abeona Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3090 holding.
  • Tower Research Capital (TRC) first reported a position in Abeona Therapeutics in Q4 2014 and has held it in 39 quarters since.
  • Tower Research Capital (TRC)'s Abeona Therapeutics position peaked at $161K in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.